Masimo Introduces the MX-7™ rainbow SET® Technology Board for Original Equipment Manufacturing Partners
July 19 2021 - 8:00AM
Business Wire
Masimo (NASDAQ: MASI) announced today the release of MX-7™, its
latest and most advanced rainbow SET® board. Designed for
integration into the more than 200 multi-parameter monitors
available from its more than 90 original equipment manufacturing
(OEM) partners, MX-7 has the ability to support all 13 of Masimo’s
SET® pulse oximetry and rainbow® Pulse CO-Oximetry measurements in
an advanced module re-engineered to reduce power needs.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210719005242/en/
Masimo MX-7™ rainbow SET® Technology
Board (Photo: Business Wire)
The MX-7 adds to Masimo’s growing portfolio of technology boards
used both in its own patient monitors and also available to its OEM
partners. MX-7 builds on the current MSX™ low-power SET® board and
MX-5™ rainbow® board by offering more efficient power utilization,
scaling its power draw based upon the combination of rainbow SET®
parameters being monitored to permit even longer battery run
times.
The MX-7 offers the full suite of Masimo’s advanced noninvasive
SET® and rainbow® parameters. Masimo SET® pulse oximetry has been
clinically proven to help care teams enhance patient safety and
improve patient outcomes; in fact, more than 100 independent and
objective studies have shown that Masimo SET® outperforms other
pulse oximetry technologies during motion and low perfusion
conditions, providing clinicians with increased sensitivity and
specificity to make critical care decisions.1 SET® has also been
shown to help clinicians reduce severe retinopathy of prematurity
in neonates,2 improve CCHD screening in newborns,3 and, when used
for continuous monitoring with Masimo Patient SafetyNet™ in
post-surgical wards, reduce deaths due to opioid overdose and
reduce rapid response team activations, ICU transfers, and
costs.4-7
By leveraging additional wavelengths of light and breakthrough
signal processing, Masimo rainbow® technology allows clinicians to
noninvasively and continuously monitor multiple advanced parameters
that previously could only be measured using invasive
techniques.
Among other rainbow SET® parameters, MX-7 offers:
- Masimo SET® SpO2 (oxygen saturation) and pulse rate (PR).
- Noninvasive and continuous hemoglobin monitoring, SpHb®, which
offers real-time visibility to changes, or lack of changes, in
hemoglobin between invasive samples. Continuous monitoring with
SpHb monitoring as part of patient blood management (PBM) programs
has been found to improve numerous outcomes.8-14
- Pleth Variability Index (PVi®), an index of continuous,
noninvasive, dynamic indication of fluid responsiveness in select
populations of mechanically ventilated adult patients.
- SpMet®, which allows clinicians to noninvasively and
continuously monitor levels of methemoglobin in the blood.
- SpCO®, a noninvasive and continuous measurement of the carbon
monoxide levels in arterial blood.
- Acoustic respiration rate (RRa®), which uses acoustic signal
processing to provide noninvasive and continuous monitoring of
respiration rate for all patient populations.
- Plethysmographic respiration rate (RRp®), which allows
clinicians to seamlessly implement monitoring of this key vital
sign without additional equipment by using the same SET® pulse
oximetry sensor that monitors oxygen saturation (SpO2).
- Oxygen Reserve Index (ORi™), a noninvasive and continuous
parameter intended to provide additional insight into a patient’s
oxygen status under supplemental oxygen.
Joe Kiani, Founder and CEO of Masimo, said, “The MX-7 board
represents that ongoing drive for innovation and improvement,
making sure that our full suite of cutting edge SET® and rainbow®
measurements are universally available to all of our
customers.”
ORi has not received FDA 510(k) clearance and is not available
for sale in the United States.
@Masimo | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. Our mission is to improve patient outcomes, reduce the
cost of care, and take noninvasive monitoring to new sites and
applications. Masimo SET® Measure-through Motion and Low Perfusion™
pulse oximetry, introduced in 1995, has been shown in over 100
independent and objective studies to outperform other pulse
oximetry technologies.1 Masimo SET® has also been shown to help
clinicians reduce severe retinopathy of prematurity in neonates,2
improve CCHD screening in newborns,3 and, when used for continuous
monitoring with Masimo Patient SafetyNet™ in post-surgical wards,
reduce rapid response team activations, ICU transfers, and
costs.4-7 Masimo SET® is estimated to be used on more than 200
million patients in leading hospitals and other healthcare settings
around the world,15 and is the primary pulse oximetry at 9 of the
top 10 hospitals as ranked in the 2020-21 U.S. News and World
Report Best Hospitals Honor Roll.16 Masimo continues to refine SET®
and in 2018, announced that SpO2 accuracy on RD SET® sensors during
conditions of motion has been significantly improved, providing
clinicians with even greater confidence that the SpO2 values they
rely on accurately reflect a patient’s physiological status. In
2005, Masimo introduced rainbow® Pulse CO-Oximetry technology,
allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth
Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve
Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7® and
Radius PPG™, portable devices like Rad-67®, fingertip pulse
oximeters like MightySat® Rx, and devices available for use both in
the hospital and at home, such as Rad-97®. Masimo hospital
automation and connectivity solutions are centered around the
Masimo Hospital Automation™ platform, and include Iris® Gateway,
iSirona™, Patient SafetyNet, Replica™, Halo ION™, UniView®, UniView
:60™, and Masimo SafetyNet™. Additional information about Masimo
and its products may be found at www.masimo.com. Published clinical
studies on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
ORi and RPVi have not received FDA 510(k) clearance and are not
available for sale in the United States. The use of the trademark
Patient SafetyNet is under license from University HealthSystem
Consortium.
References
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General
Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With
Sedative and Analgesic Medications: Impact of Continuous Monitoring
on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14
Mar. DOI: 10.1097/PTS.0000000000000696.
- Ehrenfeld JM et al. Continuous Non-invasive Hemoglobin
Monitoring during Orthopedic Surgery: A Randomized Trial. J Blood
Disorders Transf. 2014. 5:9. 2.
- Awada WN et al. Continuous and noninvasive hemoglobin
monitoring reduces red blood cell transfusion during neurosurgery:
a prospective cohort study. J Clin Monit Comput. 2015 Feb 4.
- Imaizumi et al. Continuous and noninvasive hemoglobin
monitoring may reduce excessive intraoperative RBC transfusion.
Proceedings from the 16th World Congress of Anaesthesiologists,
Hong Kong. Abstract #PR607.
- Kamal AM et al. The Value of Continuous Noninvasive Hemoglobin
Monitoring in Intraoperative Blood Transfusion Practice During
Abdominal Cancer Surgery. Open J Anesth. 2016;13-19.
- Ribed-Sánchez B et al. Economic Analysis of the Reduction of
Blood Transfusions during Surgical Procedures While Continuous
Hemoglobin Monitoring is Used. Sensors. 2018, 18, 1367;
doi:10.3390/s18051367.
- Cros J et al. Continuous hemoglobin and plethysmography
variability index monitoring can modify blood transfusion practice
and is associated with lower mortality. J Clin Monit Comp. 3 Aug
2019. https://doi.org/10.1007/s10877-019-00367-z.
- Merolle L et al. Postoperative patient blood management:
transfusion appropriateness in cancer patients. Blood Transfus
2020; 18: 359-65 DOI 10.2450/2020.0048-20.
- Estimate: Masimo data on file.
-
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo MX-7™ and rainbow
SET®. These forward-looking statements are based on current
expectations about future events affecting us and are subject to
risks and uncertainties, all of which are difficult to predict and
many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in
our forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to
our belief that Masimo's unique noninvasive measurement
technologies, including Masimo MX-7 and rainbow SET®, contribute to
positive clinical outcomes and patient safety; risks related to our
belief that Masimo noninvasive medical breakthroughs provide
cost-effective solutions and unique advantages; risks related to
COVID-19; as well as other factors discussed in the "Risk Factors"
section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at the
SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press
release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of today's date. We do not undertake any obligation to update,
amend or clarify these statements or the "Risk Factors" contained
in our most recent reports filed with the SEC, whether as a result
of new information, future events or otherwise, except as may be
required under the applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210719005242/en/
Masimo Evan Lamb 949-396-3376 elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2023 to Apr 2024